Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 18, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,085,000 ordinary shares of 25 pence each.
- Purchase Price: 1,313.432 pence per share.
- Treasury Holdings: Following the purchase, the company holds 396,722,158 shares in Treasury.
- Treasury Percentage: Treasury shares represent 7.05% of total voting rights.
- Shares in Issue: 5,626,774,102 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares due to the repurchase of 2,085,000 shares on September 18, 2007. Consequently, the total number of shares held in Treasury increased to 396,722,158. The filing does not provide comparative data against prior periods for operational metrics.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,626,774,102) for calculating ownership thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (396,722,158) and its impact on total voting rights (7.05%).
- Note that this filing is a notification of a specific transaction and does not contain quarterly or annual financial results.